Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
38.72
+0.10 (+0.25%)
Streaming Delayed Price
Updated: 3:04 PM EDT, Sep 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,640,033
Open
38.81
Bid (Size)
38.71 (200)
Ask (Size)
38.72 (1,100)
Prev. Close
38.62
Today's Range
38.41 - 38.83
52wk Range
35.12 - 64.16
Shares Outstanding
N/A
Dividend Yield
6.59%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
↗
September 24, 2026
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
Via
The Motley Fool
Topics
Intellectual Property
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
↗
September 23, 2026
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.
Via
MarketBeat
Performance
YTD
-26.1%
-26.1%
1 Month
-20.4%
-20.4%
3 Month
-18.7%
-18.7%
6 Month
+6.4%
+6.4%
1 Year
-34.1%
-34.1%
More News
Read More
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
↗
September 23, 2026
Via
MarketBeat
Topics
Intellectual Property
Lawsuit
Why Viking Therapeutics Stock Skyrocketed on Tuesday
↗
September 23, 2026
Via
The Motley Fool
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems
↗
September 22, 2026
Via
The Motley Fool
Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?
↗
September 22, 2026
Via
The Motley Fool
Topics
Intellectual Property
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction
↗
September 21, 2026
Via
MarketBeat
Why Novo Nordisk Stock Just Crashed
↗
September 21, 2026
Via
The Motley Fool
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.
↗
September 17, 2026
Via
The Motley Fool
This Trend is Excellent News for Eli Lilly and Its Investors
↗
September 17, 2026
Via
The Motley Fool
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?
↗
September 16, 2026
Via
The Motley Fool
Topics
Economy
Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything
↗
September 15, 2026
Via
The Motley Fool
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026
↗
September 15, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 15, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
↗
September 13, 2026
Via
The Motley Fool
Could This New Opportunity Be Worth Billions for Novo Nordisk?
↗
September 11, 2026
Via
The Motley Fool
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 10, 2026
Via
The Motley Fool
Topics
Intellectual Property
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
↗
September 10, 2026
Via
The Motley Fool
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
↗
September 10, 2026
Via
The Motley Fool
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
↗
September 08, 2026
Via
The Motley Fool
Topics
Intellectual Property
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now
↗
September 08, 2026
Via
The Motley Fool
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?
↗
September 07, 2026
Via
The Motley Fool
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.
↗
September 05, 2026
Via
The Motley Fool
2 Stocks Down 8% or More That Are Screaming Buys Right Now
↗
September 04, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
↗
August 30, 2026
Via
The Motley Fool
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 38.72
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/25/26 03:04 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.